The cookie is used to store the user consent for the cookies in the category "Analytics". This cookie is set by GDPR Cookie Consent plugin. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement". Amazon has updated the ALB and CLB so that customers can continue to use the CORS request with stickness.
This cookie is used for load balancing services provded by Amazon inorder to optimize the user experience.
These cookies ensure basic functionalities and security features of the website, anonymously. Sequential use of different T-cell redirection therapies is possible and can lead to deep and durable responses following relapse after BiAb therapy in RRMM.Necessary cookies are absolutely essential for the website to function properly. T-cell redirection therapy as first or second salvage was feasible and associated with a median PFS1 of 28.9 months and PFS2 of 30.9 months and an OS of 62% at 2 years. Ten patients received T-cell redirection as second salvage. The most common first salvage was T-cell redirection in nineteen patients (ten BiAb and nine CAR-T). After the BiAb trial, patients were followed for a median of 30.5 months and received a median of two additional salvage therapies (range: 1-9). They had a median of 6 prior therapy lines, 89% were triple-class refractory and 44% were penta-drug refractory. Patients had a median age of 67 years and 78% had high-risk cytogenetics.
Progression-free survival (PFS) to first- (PFS1) and second salvage therapy (PFS2), and overall survival (OS) were estimated using the Kaplan-Meier method. We identified fifty-eight patients progressing after a BiAb trial at the Mount Sinai Hospital. Data regarding outcomes after relapse following BiAbs are urgently needed to develop strategies for sequencing salvage therapies. T-cell redirection therapy with chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BiAbs) has shown promising efficacy in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients, leading to the approval of two CAR-T cell products and numerous BiAb trials.
0 kommentar(er)
